Dimensional Fund Advisors LP Sells 34,676 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Dimensional Fund Advisors LP lowered its holdings in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 6.3% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 518,203 shares of the biopharmaceutical company’s stock after selling 34,676 shares during the period. Dimensional Fund Advisors LP owned about 0.25% of Sangamo Therapeutics worth $186,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of SGMO. State Board of Administration of Florida Retirement System increased its holdings in Sangamo Therapeutics by 61.1% in the first quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 23,650 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Sangamo Therapeutics in the first quarter worth $331,000. Acadian Asset Management LLC increased its stake in Sangamo Therapeutics by 4.0% in the first quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company’s stock valued at $3,311,000 after purchasing an additional 192,385 shares in the last quarter. Finally, Wasatch Advisors LP raised its holdings in shares of Sangamo Therapeutics by 62.4% during the first quarter. Wasatch Advisors LP now owns 20,132,324 shares of the biopharmaceutical company’s stock valued at $13,493,000 after purchasing an additional 7,734,400 shares during the period. Institutional investors and hedge funds own 56.93% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on the company. StockNews.com began coverage on Sangamo Therapeutics in a research report on Sunday, July 28th. They issued a “sell” rating for the company. HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Sangamo Therapeutics in a report on Thursday, August 22nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, Sangamo Therapeutics presently has a consensus rating of “Hold” and an average target price of $2.67.

Sangamo Therapeutics Stock Performance

Sangamo Therapeutics stock opened at $0.93 on Tuesday. The stock has a market cap of $192.40 million, a PE ratio of -0.50 and a beta of 1.23. The firm’s 50-day simple moving average is $0.86 and its 200 day simple moving average is $0.65. Sangamo Therapeutics, Inc. has a fifty-two week low of $0.29 and a fifty-two week high of $1.48.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). The business had revenue of $0.36 million for the quarter, compared to the consensus estimate of $11.40 million. Sangamo Therapeutics had a negative return on equity of 273.25% and a negative net margin of 2,033.69%. As a group, analysts predict that Sangamo Therapeutics, Inc. will post -0.47 EPS for the current fiscal year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.